Uploaded May 2023 | Updated September 2026, 2 weeks ago
Insilico's latest preclinical candidate (PCC) is the Company’s 12th PCC in the past two years. It is an orally available inhibitor of ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia, a rare genetic disorder characterized by abnormal development of the bones and teeth.
The molecule has a distinctly novel structure, robust anti-tumor efficacy in in vivo studies, and a favorable safety profile. It was designed using Insilico’s drug design engine Chemistry42, which connects generative AI algorithms with medicinal and computational chemistry methodologies to generate novel molecular structures with optimized properties.
eurekalert.org/news-releases/989778
Insilico's latest preclinical candidate (PCC) is the Company’s 12th PCC in the past two years. It is an orally available inhibitor of ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia, a rare genetic disorder characterized by abnormal development of the bones and teeth.
The molecule has a distinctly novel structure, robust anti-tumor efficacy in in vivo studies, and a favorable safety profile. It was designed using Insilico’s drug design engine Chemistry42, which connects generative AI algorithms with medicinal and computational chemistry methodologies to generate novel molecular structures with optimized properties.
eurekalert.org/news-releases/989778
